Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)
Hong Kong
· Delayed Price · Currency is HKD 4.590
-0.030 (-0.65%)
May 13, 2025, 2:33 PM HKT
HKG:9989 Revenue
Shenzhen Hepalink Pharmaceutical Group had revenue of 1.39B CNY in the quarter ending March 31, 2025, with 1.53% growth. This brings the company's revenue in the last twelve months to 5.28B, down -4.31% year-over-year. In the year 2024, Shenzhen Hepalink Pharmaceutical Group had annual revenue of 5.26B, down -3.17%.
Revenue (ttm)
5.28B CNY
Revenue Growth
-4.31%
P/S Ratio
2.81
Revenue / Employee
2.74M CNY
Employees
1,926
Market Cap
15.90B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.26B | -172.06M | -3.17% |
| Dec 31, 2023 | 5.43B | -1.73B | -24.14% |
| Jan 1, 2023 | 7.16B | 794.23M | 12.48% |
| Jan 1, 2022 | 6.37B | 1.03B | 19.38% |
| Dec 31, 2020 | 5.33B | 707.42M | 15.30% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Alibaba Health Information Technology | 31.39B |
| Akeso | 2.26B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |